Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Outcome of early switching of tenofovir disoproxil fumarate in HIV-infected patients with tenofovir-induced nephrotoxicity
TCTR20190307003Phase 3Recruiting
- Sponsor
- N/A
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tenofovir disoproxil fumarate in human immunodeficiency virus infection (HIV), nephrotoxicity, sponsored by N/A. Started Sep 2017; status: recruiting.
02
Drugs
tenofovir disoproxil fumarate
03
Conditions
human immunodeficiency virus infection (HIV)nephrotoxicity
Beyond the preview
Go deeper on TCTR20190307003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20190307003.